Introduction
The 88 kDa glycoprotein PC cell-derived growth factor (PCDGF/GP88) is an autocrine growth factor, first isolated from the highly tumorigenic mouse teratoma PC cells (1) . PCDGF/GP88, also known as progranulin, is the largest member of the granulin/epithelin family of cystein-rich polypeptide growth modulators (2, 3) . It has been reported that PCDGF/ GP88 stimulated the proliferation and survival of several cell types of mesenchymal and epithelial origin by stimulating MAP kinase, PI-3 kinase and FAK kinase pathways (2, 3) . Interestingly, over-expression of PCDGF/GP88 was found in several cancer cell lines and/or tumor tissues including breast cancer (4), ovarian cancer (5), renal cell carcinoma (6) , multiple myeloma (7) and glioblastoma (8) . In breast cancer cells, PCDGF/GP88 has been shown to play a critical role in tumorigenesis. PCDGF/GP88 over-expression correlated positively with the acquisition of estrogen-independent growth, tamoxifen resistance and tumorigenicity (4, 9, 10) . Inhibition of PCDGF/GP88 expression by antisense cDNA transfection in MDA-MB-468 cells resulted in a complete inhibition of tumor growth in nude mice. In addition, it was demonstrated that PCDGF/GP88 prevented the apoptotic effect of tamoxifen in estrogen receptor positive breast cancer cells (10) . Pathological studies with breast carcinoma biopsies revealed that PCDGF/GP88 was expressed in 80% invasive ductal carcinoma in correlation with poor prognosis markers such as tumor grade, p53 expression and Ki67 index whereas benign lesions were mostly negative (11) . In addition, pathological studies in ovarian tumors indicated that PCDGF/GP88 was highly expressed in invasive epithelial ovarian tumors when compared with tumors with low malignant potential (5) . Taken together, these studies would suggest that PCDGF/GP88 plays a role in invasion in addition to stimulating proliferation of tumor cells. Metastasis is a hallmark of cancer transition from a non-invasive to an invasive phenotype. Both invasion through extracellular matrix and neovascularization are required steps for promoting metastasis. Tumor cells secrete proteases such as matrix metalloproteinases (MMPs) to degrade the basement membrane and stroma, allowing malignant cells to invade other surrounding tissues. The expression of these enzymes by the cancer cells is required for tumor invasion (12) . Among the members of the metalloprotease family, MMP-9 has been shown to play a major role in the invasiveness of mammary epithelial cells (13EE15). MMP-9 is induced in several cell types by a variety of cytokines, growth factors and oncogenes (16EE18).
Angiogenesis is another major event required for tumor growth and tumor progression. This process is regulated by angiogenic factors, released by the tumor cells or by stroma cells surrounding the tumors (19) . Vascular endothelial growth factor (VEGF) is the most potent angiogenic factor for several cancers (20) . Strong VEGF staining was frequently found in the invasive ductal carcinoma (21) .
In this present study, we investigated the potential role of PCDGF/GP88 in metastasis of human breast cancer cells by investigating its ability to stimulate cell migration, metalloprotease activity and VEGF expression.
Materials and methods
Materials G418, Taq polymerase and Superscript II were obtained from Gibco BRL (Gaithersburg, MD). Growth factor reduced phenol red-free Matrigel was purchased from Becton Dickinson Labware (Bedford, MA). Fetal bovine serum (FBS) was from Sigma (St Louis, MO). Oligonucleotide primers used in the RTEEPCR were synthesized by the Biopolymer Core Laboratory of the University of Maryland (Baltimore, MD). Enhanced chemiluminescence kit was obtained from Pierce (Rockford, IL).
Cell culture
The ER human breast cancer cell line MCF-7 was obtained from ATCC (Manassas, VA). PCDGF/GP88 over-expressing MCF-7 cells (O4 cells) and empty vector control cells (MCF-7 EV) have been described elsewhere (9,10).
Abbreviations: MMP-9, matrix metalloprotease-9; PCDGF, PC cell-derived growth factor.
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Cells were maintained in DMEM/F12 supplemented with 5% FBS in the presence of 400 mg/ml G418. RTEEPCR MCF-7 EV cells were cultivated in phenol red-free DMEM/F12 supplemented with 1% charcoal-stripped serum and 1 nM 17-b estradiol (E2), PCDGF/GP88 (400 ng/ml) or vehicle only. O4 cells were cultivated in phenol red-free DMEM/ F12 with 1% charcoal-stripped serum. For the experiments with tamoxifen, 1 mM tamoxifen was added to the culture medium. Medium was changed at day 3. RNA samples were collected at day 5 using Trizol. Five micrograms of total RNA were reverse transcribed into single strand cDNA by Superscript II (Gibco), using 250 ng of random hexamer (Gibco) as primer. The RT reaction was carried out for 1 h at 42 C in 10 mM TrisEEHCl (pH 8.3), 2.5 mM MgCl 2 , 50 mM KCl, DTT 0.01 M and dNTP (each 0.5 mM). A total of 30EE35 PCR cycles depending on the gene amplified was performed, followed by electrophoresis on 1% agarose gel. The specific primer pairs are: for glyceraldehyde 3 Matrigel migration assay PCDGF/GP88 over-expressing cells (O4) and MCF-7 EV were seeded at a density of 1 Â 10 5 cells onto matrigel coated inserts (100 mg/cm 2 ; 8 mm pore size) in 24-well plates (Beckton Dickinson Labware, Bedford, MA). The cells were incubated in phenol red-free DMEM/F12 medium supplemented with 1% charcoal-stripped serum with or without 400 ng/ml of PCDGF/GP88. After a 72-h incubation, the cells on the inserts were fixed with 4% paraformaldehyde in PBS for 10 min, washed with PBS and stained with hematoxylin qs (Vector Laboratories, Burlingame, CA). The cells on the upper side of the inserts were removed with a cotton swab. Fixed cells that migrated to the lower side of the filters were counted with a microscope.
Soft agar assay
Anchorage-independent cell growth was determined by soft agar colony forming assay. 10 000 MCF-7 or O4 cells were inoculated in 1 ml of 0.33% agar in tissue culture medium containing 10% FBS in 35 mm plates over a bottom layer of 1.5 ml of 0.6% agar in DMEM/F12 supplemented with 10% FBS. The cells were allowed to grow for 21 days with re-feeding with 200 ml of DMEM/ F12, every 3 days. Colonies were stained with 0.005% crystal violet for an hour. Experiments were carried out in quadruplicate.
Zymograph assay and western blot for MMP-9
Five million cells were plated in DMEM/F12 medium with 5% FBS. After 24 h incubation and subsequent washing, the medium was replaced with serum-free medium supplemented with vehicle only or 400 ng/ml of PCDGF/GP88. Medium was collected 24 h later and concentrated with Centriprep YM-10 (Millipore, Billerica, MA). The amount of concentrated medium used in the assay was normalized to the cell number. Samples were diluted in 50 mM TrisEEHCl pH 7.4 without reducing agent and separated in a 7.5% sodium dodecylsulfateEE polyacrylamide gel electrophoresis (SDSEEPAGE) containing 1 mg/ml gelatin. After electrophoresis, the gels were washed in 2.5% Triton X-100 for 30 min and incubated for 16 h at 37 C in 50 mM TrisEEHCl pH 7.4, 200 mM NaCl, 10 mM CaCl 2 . Gels were stained with Coomassie brilliant blue R-250 and destained in 40% methanol, 10% acetic acid until clear bands appeared.
For western blot analysis of MMP-9 expression, conditioned media were collected and concentrated as described above. Samples were mixed with Laemmli buffer in reducing conditions and separated in a 7.5% SDSEEPAGE. Proteins were transferred to PVDF membrane for western blot analysis of MMP-9 expression with 1 mg/ml anti-human MMP-9 mouse monoclonal antibody from Oncogene Research (Boston, MA), followed by incubation with HRP-conjugated goat anti-mouse-IgG. Immunoreactive proteins were detected by enhanced chemiluminescence kit (Pierce, Rockford, IL).
Statistical analysis
All experiments were conducted in triplicates or quadruplicates and repeated at least three times. Data were analyzed by Student's t test for mean comparison and statistical significance (P 5 0.05). The values are reported as mean AE SEM.
Results

PCDGF/GP88 expression stimulates anchorage-independent growth in vitro
The ability of PCDGF/GP88 to stimulate anchorage-independent growth of MCF-7 cells was first examined. For this purpose, we compared the ability of MCF-7 cells over-expressing PCDGF/GP88 (O4 cells) and control cells (MCF-7 EV) to form colonies in soft agar. As shown in Figure 1 , there was a 4.5-fold increase in the number of colonies formed by O4 cells when compared with MCF-7 EV cells (P 5 0.05).
Effect of PCDGF/GP88 on cell invasion through matrigel
To assess the effect of PCDGF/GP88 on extracellular matrix invasion, we examined the ability of PCDGF/GP88 to stimulate cell migration through matrigel. As shown in Figure 2 , the number of cells migrating through matrigel was significantly higher in MCF-7 EV cells treated with PCDGF/GP88 when compared with untreated cells (2.9-fold increase, P 5 0.05). Similarly, increased cell migration was also observed in PCDGF/GP88 over-expressing MCF-7 cells (O4 cells) when compared with control MCF-7 EV cells (3.2-fold increase, Fig. 1 . Effect of PCDGF/GP88 on anchorage-independent growth. MCF-7 EV and O4 cells were cultivated in 35 mm plates in 0.33% agar over a bottom layer of 0.6% agar in DMEM/F12 supplemented with 10% FBS. After 21 days, colonies were stained with 0.005% crystal violet and counted as described in the Materials and methods section. Fig. 2 . PCDGF/GP88 stimulates Matrigel invasion. MCF-7 EV and O4 cells were inoculated on Falcon cell culture inserts (8 mm pore size) coated with growth factor reduced phenol red-free Matrigel (100 mg/cm 2 ). Cells were cultured with phenol red-free DMEM/F12 supplemented with 1% charcoal-stripped serum. MCF-7 cells were cultivated in the same medium with or without supplement of 400 ng/ml of PCDGF/GP88. After a 72-h incubation, the inserts were fixed in 4% paraformaldehyde and stained with hematoxylin. The cells on the lower side of the inserts were counted under the microscope. Data shown here represents the results from three independent experiments.
PCDGF/GP88 promotes MMP-9 secretion by MCF-7 cells
We investigated the effect of PCDGF/GP88 on MMP-9 expression using two assays. A zymograph assay, using gelatin as substrate, was used to determine whether PCDGF/GP88 stimulated the secretion of gelatinase from MCF-7 cells. As shown in Figure 3 (upper panel) , untreated MCF-7 EV cells displayed a minimal gelatinase activity. Treatment of the cells with 400 ng/ml of PCDGF/GP88 for 24 h prior to collecting the medium resulted in the presence of a strong gelatinolytic activity migrating at a molecular weight corresponding to MMP-9. Increased gelatinolytic activity was also observed in PCDGF/GP88 expressing MCF-7 cells (O4 cells).
The stimulation of MMP-9 secretion by PCDGF/GP88 was examined by immunoblot analysis using anti-MMP-9 specific antibody. As shown in Figure 3 (lower panel), the level of MMP-9 protein secreted in the culture medium was greater in MCF-7 EV treated with PCDGF/GP88 and O4 cells than in control untreated MCF-7 EV cells (11.4-and 9.8-fold, respectively).
PCDGF/GP88 promotes VEGF expression in MCF-7 cells
VEGF is the major angiogenic factor involved in tumor neovascularization. The ability of PCDGF/GP88 to stimulate VEGF expression in MCF-7 cells was investigated. Reverse transcription PCR was used to examine VEGF expression in MCF-7 cells. The primer set selected for VEGF (see Materials and methods section) permitted the detection of the six VEGF transcripts: VEGF 121 , VEGF 145 , VEGF 165 , VEGF 183 , VEGF 189 and VEGF 206 (22) . Only three transcripts VEGF 121 , VEGF 165 and VEGF 189 were detectable in MCF-7 cells. As shown in Figure 4 , treatment of MCF-7 cells for 5 days with PCDGF/ GP88 induced a 2.4-fold increase in the expression of VEGF transcripts. This stimulation was comparable with the one observed with a 5 day treatment with estradiol (3.2-fold), a known stimulator of VEGF expression in MCF-7 cells (23, 24) .
Interestingly tamoxifen, which inhibited the effect of estradiol on VEGF, was unable to prevent the stimulation of VEGF observed with PCDGF/GP88 in MCF-7 EV cells ( Figure 5 ).
Increased VEGF expression was also observed in PCDGF/ GP88 over-expressing cells when compared with MCF-7 EV cells. As shown in Figure 6 , tamoxifen treatment of the PCDGF/GP88 over-expressing cells (O4 cells) further stimulated VEGF expression in PCDGF/GP88 over-expressing cells Fig. 3 . Stimulation of MMP-9 expression by PCDGF/GP88. Gelatinolytic activity of MCF-7 EV, MCF-7 EV PCDGF/GP88 (P) and O4 cells was determined as described in the Materials and methods section (upper panel). MMP-9 expression in the cells was determined by western blot using anti-MMP9 antibody (lower panel). (1.9-fold). This result indicated that PCDGF/GP88 over-expression stimulated VEGF expression and tamoxifen treatment further increased VEGF expression in cells overexpressing PCDGF/GP88 or exogenously treated with PCDGF/GP88.
Discussion
The results provided here demonstrate that PCDGF/GP88 induces anchorage-independent growth, cell migration and invasiveness of MCF-7 breast cancer cells. The stimulation of anchorage-independent growth of MCF-7 cells by PCDGF/ GP88 is in agreement with our previous studies indicating that PCDGF/GP88 over-expressing MCF-7 cells displayed an increased tumorigenesis in mouse xenografts (10) . Similar results have been reported with adrenal carcinoma SW13 cells, as well as non-transformed renal epithelial MDCK cells, where over-expression of PCDGF/GP88 (progranulin) rendered the cells more clonogenic in soft agar assay (25) . In addition, over-expression in SW13 cells increased tumorigenicity in mouse xenografts (25) .
The acquisition of phenotypic characteristics such as migration and invasiveness are required for a cancer cell to successfully initiate the metastatic cascade. In this study, we have determined that PCDGF/GP88 over-expressing cells displayed an increased capacity of migrating through extracellular matrix (Figure 2) . The fact that PCDGF/GP88 added exogenously also increased migration of MCF-7 cells would indicate that this is a direct effect of PCDGF/GP88. Stimulation of cell migration by PCDGF/GP88 had been reported previously for dermal fibroblasts and endothelial cells (26) indicating that this effect is observed in normal as well as tumor cells. Several growth factors such as FGFs (27, 28) , and heregulinb1 (29) have been reported as promoters of cell migration through matrigel via regulating matrix metalloprotease secretion. Among the various matrix metalloproteases, MMP-9 expression is elevated in the association with increased metastatic potential in many cancer types including breast cancer (30) . It has been shown that MMP-9 activity is correlated with tumor grade and invasion in canine mammary adenocarcinoma (31) . MMP-9 promoter activity is induced in invasive mammary carcinogenesis but is inactive in benign papillomas and in dysplastic papillomas (32) . Heregulin, EGF and amphiregulin also induced expression and secretion of MMP-9 in MCF-7 via multiple signaling pathways including MAP kinase cascade, PKC and PI3-K in SKBR-3 cells (33, 34) . Inhibition of ERK1 activation is associated with decreased MMP-9 secretion and reduction of in vivo invasiveness (35) . We show here that PCDGF/GP88 treatment or over-expression induces secretion and gelatinolytic activity of MMP-9 in MCF-7 cells. Since PCDGF/GP88 is known to activate MAPK and PI3K pathways in several cell lines including breast cancer cells (2, 3, 7, 9) , it is possible that either one or both pathways are required for MMP-9 up-regulation by PCDGF/GP88 observed here. It has been shown previously in SW-13 cells that progranulin stimulates mRNA expression of MMP-13 and MMP-17 (25) . MMP-13 is found in rheumatoid lesion, ulcer, malignant breast tumor, squamous cell carcinomas and chondrosarcomas whereas MMP-17 is poorly described. However, whether PCDGF/GP88 activated mRNA expression of MMP-9 in SW13 cells was not determined.
Neovascularization or angiogenesis is a crucial process required for solid tumor progression beyond a certain size. We have shown previously that PCDGF/GP88 over-expression promotes tumor growth in vivo and that PCDGF/GP88 overexpressing tumors had a higher level of VEGF and angiopoietin-1 than MCF-7 tumors (10).We show here that PCDGF/ GP88 stimulates VEGF expression in MCF-7 cells in culture. The data would suggest that the increased VEGF expression observed in the tumors was due to a direct stimulation of VEGF expression in the tumor cells by PCDGF/GP88 rather than to an indirect effect on stromal cells found in the tumor environment. Several growth factors including EGF, PDGF, TNF-a, TGF-b stimulate VEGF expression in several cells (36, 37) . Interestingly, He et al. showed that PCDGF/GP88 induced human microvascular endothelial cell proliferation and promote tube-like structure, suggesting the role in normal angiogenesis (26) . Our results showing that PCDGF/GP88 induced VEGF expression would provide a pathway by which PCDGF/GP88 stimulated vascularization is mediated.
Several reports have demonstrated an association between VEGF and MMP-9 expression in several cancer types. VEGF enhanced expression of MMP-9 through Flt-1 in vascular smooth muscle cells (38) whereas Bergers et al. found that MMP-9 acted as an angiogenic switch by causing greater accessibility of VEGF to its receptors (39) . In addition, Kurizaki et al. found that pro-MMP-9 expression correlated with the higher intratumoral microvessel density and thymidine phosphorylase expression (14) . Taken together, the fact that PCDGF/GP88 stimulates both MMP-9 secretion and VEGF would suggest that PCDGF/GP88 participates in facilitating this correlation W.Tangkeangsirisin and G.Serrero between matrix metalloproteases expression and tumor angiogenesis in human breast cancer cells.
Our previous in vivo study showed that PCDGF/GP88 overexpressing MCF-7 cells are more tumorigenic in nude mice xenograft model than MCF-7 cells. Moreover, treatment of the PCDGF/GP88 over-expressing cells with tamoxifen further stimulated tumor growth instead of inhibiting it as observed for MCF-7 cells (10). It is suggested that the stimulation of VEGF expression by PCDGF/GP88 and its potentiation by tamoxifen would support the increased tumor growth observed in vivo. Over-expression of VEGF in MCF-7 cells has been shown to promote cell proliferation and provide estrogenindependent tumor growth in vitro and in vivo, suggesting an autocrine/paracrine-activation loop by VEGF (40) . It is possible that the potentiation of tumor growth in vivo, observed with tamoxifen and PCDGF/GP88, may be mediated by their stimulatory effect on VEGF expression. We show here that the stimulation of VEGF expression by tamoxifen is also observed in vitro in PCDGF/GP88 over-expressing cells as well as in MCF-7 cells treated with estradiol and PCDGF/GP88. The mechanism underlying this effect is at present unknown. We have shown previously that PCDGF/GP88 up-regulated Bcl-2 expression in MCF-7 and prevented its down regulation by tamoxifen (10) . A relationship between bcl-2 and VEGF expression has recently been reported in human melanoma via stimulation of VEGF mRNA stability and promoter-activation (41) . The existence of a similar positive association between bcl-2 and VEGF in MCF-7 cells could explain the VEGF stimulation observed with the combination of tamoxifen and PCDGF/GP88 treatment in MCF-7 cells treated with estradiol. Interestingly, estrogen and tamoxifen have been also shown to stimulate VEGF expression in a variety of cell systems including cultured vascular muscle cells (42) , uterus (43, 44) and endometrial cells (45) . In MCF-7 cells, tamoxifen has been occasionally reported as stimulating VEGF mRNA expression in vitro (46) . In vivo, tamoxifen treatment has been associated with higher plasma VEGF level in pre-and postmenopausal women (47) .
We have shown previously that PCDGF/GP88 overexpression in MCF-7 cells mediated tumorigenicity, tamoxifen resistance and estrogen-independent growth. The data presented here would propose a potential role of PCDGF/GP88 in mediating breast tumor metastasis and angiogenesis via promoting MMP-9 and VEGF expression, implying that PCDGF/GP88 plays a significant role in many aspects of breast cancer.
